While Prelude Therapeutics Inc has underperformed by -3.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRLD fell by -83.90%, with highs and lows ranging from $6.80 to $0.63, whereas the simple moving average fell by -68.22% in the last 200 days.
On September 19, 2024, H.C. Wainwright Upgraded Prelude Therapeutics Inc (NASDAQ: PRLD) to Buy. A report published by Barclays on June 20, 2024, Downgraded its rating to ‘Underweight’ for PRLD. JMP Securities also rated PRLD shares as ‘Mkt Outperform’, setting a target price of $7 on the company’s shares in an initiating report dated March 13, 2024. Morgan Stanley December 19, 2023d its ‘Equal-Weight’ rating to ‘Underweight’ for PRLD, as published in its report on December 19, 2023. BofA Securities’s report from November 21, 2022 suggests a price prediction of $6 for PRLD shares, giving the stock a ‘Underperform’ rating. Morgan Stanley also rated the stock as ‘Equal-Weight’.
Analysis of Prelude Therapeutics Inc (PRLD)
One of the most important indicators of Prelude Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -69.01% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and PRLD is recording 244.09K average volume. On a monthly basis, the volatility of the stock is set at 11.12%, whereas on a weekly basis, it is put at 12.17%, with a gain of 6.67% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.50, showing growth from the present price of $0.77, which can serve as yet another indication of whether PRLD is worth investing in or should be passed over.
How Do You Analyze Prelude Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 47.97%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 31.35% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PRLD shares are owned by institutional investors to the tune of 31.35% at present.
